SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS® Test

Dana Farber Collaboration to Bring PARIS® Test to Patients with CNS Cancers

PARIS® Test Identified Effective Therapy for Patient with Terminal Ovarian Cancer

Prospective joint venture will accelerate precision medicine in Europe by harnessing innovations in high-throughput drug testing and 3D tumor cell culture.

Strong Predictive Value of Organoid-Based PARIS® Test to Identify Personalized Treatments in Advanced Cancers Presented at 2021 ASCO Annual Meeting

SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS® Test at 2021 ASCO Annual Meeting

SEngine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian Cancer

Predictive Value of PARIS® Test in Ovarian Cancer Patients at 2021 AACR Annual Conference

Precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids

SEngine to present Predictive Value of PARIS® Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium

Novel Drug Combinations for PARP Inhibitor Resistant Ovarian Cancer in Study Published in EBioMedicine

Clinical Utility demonstrated in Metastatic Colorectal Cancer Study Published in AACR’s Clinical Cancer Research

Predictive value of the PARIS® Test for personalized treatment in cholangiocarcinoma

Results of the PARIS Test showed a 92% correlation between organoid drug sensitivity and patient response to previous treatments

PARIS® Test for Oncology Drugs Based on Retrospective Analysis presented at 2020 ASCO Annual Meeting

Predictive Value of PARIS® Test, an Organoid-based Drug Response Assay, for Cholangiocarcinoma Patients presented at 2020 AACR Virtual Meeting Session II

February 2019 Pulitzer Prize Winner to Lead Scientific Advisory Board

SEngine Precision Medicine Raises $5.1 Million Series A